Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01114139 · ClinicalTrials.gov registry record · Phase 3
A Trial Comparing Ferumoxytol With Placebo for the Treatment of Iron Deficiency Anemia
A Phase 3 study, sponsored by AMAG Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 812
- Enrollment target
NCT01114139 is a Phase 3 study that has completed, run by AMAG Pharmaceuticals. The registered enrollment target is 812 participants.
The verdict
NCT01114139, a Phase 3 study, has completed, sponsored by AMAG Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 812 participants
- Enrollment target
Study Summary
To evaluate the efficacy and safety of intravenous (IV) ferumoxytol compared with placebo for the treatment of iron deficiency anemia (IDA).
Interventions
- DRUG Ferumoxytol
- OTHER Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 812 participants |
| Start Date | 2010-06-19 |
| Est. Completion | 2012-10-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01114139
The ClinicalTrials.gov registry entry for NCT01114139 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 812 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AMAG Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ferumoxytol is the first listed.
NCT01114139 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01114139 about?
NCT01114139 is a clinical study titled "A Trial Comparing Ferumoxytol With Placebo for the Treatment of Iron Deficiency Anemia". To evaluate the efficacy and safety of intravenous (IV) ferumoxytol compared with placebo for the treatment of iron deficiency anemia (IDA).
What is the current status of trial NCT01114139?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 812 participants. The study started on 2010-06-19. Estimated completion is 2012-10-22.
What interventions are being tested in trial NCT01114139?
The interventions under investigation include: Ferumoxytol (DRUG), Placebo (OTHER).
Who is sponsoring clinical trial NCT01114139?
This trial is sponsored by AMAG Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.